logo
logo
STXS stock ticker logo

Stereotaxis, Inc.

AMEX•STXS
CEO: Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2004-08-12
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Contact Information
710 North Tucker Boulevard, Suite 110, Saint Louis, MO, 63101, United States
314-678-6100
www.stereotaxis.com
Market Cap
$173.51M
P/E (TTM)
-8.0
14
Dividend Yield
--
52W High
$3.59
52W Low
$1.54
52W Range
14%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$8.64M+0.00%
4-Quarter Trend

EPS

-$0.06+0.00%
4-Quarter Trend

FCF

-$4.04M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Rises 20.3% Total revenue reached $32.4M USD in 2025, driven by system sales and full year APT acquisition contribution.
Net Loss Narrows Net loss attributable to common stockholders improved to ($22.914M) USD from ($25.353M) USD in the prior year.
Disposable Revenue Strong Disposable, service, and accessories revenue grew 21% to $22.2M USD, reflecting full year impact of APT acquisition.

Risk Factors

Operating Cash Burn Cash used in operating activities increased significantly to ($13.7M) USD, straining liquidity and capital resources.
Critical Catheter Supply Supply obligation for predominant J&J ablation catheters ended December 31, 2025; MAGiC replacement ramping up.
System Backlog Decreases System backlog fell to $9.1M USD by December 31, 2025, down from $14.4M USD in the prior year.

Outlook

Backlog Revenue Conversion Expect approximately 78% of the $9.1M system backlog to be recognized as revenue throughout the 2026 fiscal year.
Focus on New Approvals Pursuing regulatory clearances for MAGiC catheter in U.S. and expanding approvals for other key devices globally.
Control Operating Expenses Plans focus on controlling timing and spending of operating expenses while seeking additional debt or equity financing.

Peer Comparison

Revenue (TTM)

NEO stock ticker logoNEO
$727.33M
+10.1%
MDXH stock ticker logoMDXH
$159.60M
+19.8%
QTRX stock ticker logoQTRX
$138.73M
+2.4%

Gross Margin (Latest Quarter)

SMTI stock ticker logoSMTI
92.9%
+2.1pp
CVRX stock ticker logoCVRX
86.3%
+3.6pp
ARCT stock ticker logoARCT
77.9%
-19.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CVRX$227.07M-4.2-99.3%48.5%
NEO$212.37M-1.9-12.6%34.7%
QTRX$207.01M-2.0-35.2%8.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.0%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 11, 2026
|
EPS:-$0.05
|
Revenue:$8.72M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data